Rowsley to acquire TMC Life Sciences' sale warrants for RM103.75 million
ROWSLEY on Saturday updated that the consideration for the TMC Life Sciences sale warrants will be RM103.75 million (S$34.81 million) - being their volume-weighted average price traded on Bursa Securities for the one-month period leading up to March 19, 2018.
This is part of Rowsley's plans to acquire the Thomson Medical healthcare businesses from controlling shareholder Peter Lim for S$1.6 billion, to be paid mostly in stock. This was announced last December.
The deal involves Rowsley acquiring the privately-held Thomson Medical and a 70.36 per cent stake in Malaysia-listed TMC Life Sciences.
To foot the bill, Rowsley will issue Mr Lim 21.3 billion new shares at S$0.075 apiece. Mr Lim will also offload some 597.3 million TMC warrants to Rowsley in exchange for about S$40.2 million in cash, it said at the time.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Airbus net profit soars 28% in first quarter
Carrier AirAsia discloses new listing plans under RM6.8 billion units merger
Intel slides after tepid forecast spurs fears about comeback
Microsoft beats estimates as AI drives revenue
Crypto firm sues SEC to fend off oversight of Ethereum
Snap beats first-quarter expectations, shares jump 25%